Cara Therapeutics (CARA) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Key Stats

• Today's Range: $0.28 to $0.32
• 50-Day Range: $0.25 to $0.35
• 52-Week Range: $0.24 to $1.31
• Volume: 508,493 shs
• Average Volume: 912,809 shs
• Market Capitalization: $16.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.32
• Consensus Rating: Hold

Cara Therapeutics Stock Analysis - MarketRank™

Cara Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 277th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Cara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cara Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cara Therapeutics are expected to grow in the coming year, from ($1.24) to ($0.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cara Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cara Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cara Therapeutics has a P/B Ratio of 30.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.06% of the float of Cara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cara Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cara Therapeutics has recently increased by 54.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cara Therapeutics does not currently pay a dividend.

Dividend Growth

Cara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.39

Percentage of Shares Shorted

2.06% of the float of Cara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cara Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cara Therapeutics has recently increased by 54.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.18

News Sentiment

Cara Therapeutics has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for CARA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Cara Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CARA Stock Analysis - Frequently Asked Questions

How have CARA shares performed this year?

Cara Therapeutics' stock was trading at $0.7430 at the start of the year. Since then, CARA stock has decreased by 58.9% and is now trading at $0.3051.
View the best growth stocks for 2024 here.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings data on Wednesday, August, 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.10. The biopharmaceutical company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 367.97% and a negative net margin of 1,099.76%.

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' top institutional investors include Disciplined Growth Investors Inc. MN (2.03%), BNP Paribas Financial Markets (1.06%), Stifel Financial Corp (0.61%) and FMR LLC (0.38%). Insiders that own company stock include Christopher Posner, Frederique PhD Menzaghi, Scott Terrillion, Joana Goncalves, Martin Vogelbaum, Jeffrey L Ives, Ryan D Maynard and Thomas Charles Reilly.
View institutional ownership trends.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CARA
• CUSIP: N/A
• CIK: 1346830
• Web: www.caratherapeutics.com
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 55
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.32
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +660.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-118,510,000.00
• Net Margins: -1,099.76%
• Pretax Margin: -1,099.76%
• Return on Equity: -367.97%
• Return on Assets: -107.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.77
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $8.69 million
• Price / Sales: 1.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 30.51

Miscellaneous

• Outstanding Shares: 54,856,000
• Free Float: 53,155,000
• Market Cap: $16.74 million
• Optionable: Optionable
• Beta: 0.68